Page 17 - ebook
P. 17

고형암 항암치료 환자의 부작용 관리                                                       Nausea and Vomiting






                               Classification                                  Agent

                  Parenteral         Low emetic risk      Mitomycin
                                                          Mitomycin prelocalyceal solution
                                                          Mitoxantrone
                                                          Mogamulizumab
                                                          Moxetumomab
                                                          Necitumumab
                                                          Olaratumab
                                                          Omacetaxine
                                                          Paclitaxel
                                                          Paclitaxel-albumin
                                                          Pemetrexed
                                                          Pentostatin
                                                          Polatuzumab vedotin
                                                          Pralatrexate
                                                          Romidepsin
                                                          Tafasitamab-cxix
                                                          Tagraxofusp
                                                          Talimogene laherparepvec
                                                          Thiotepa
                                                          Tisagenlecleucel
                                                          Topotecan
                                                          Ziv-aflibercept
                                    Minimal emetic risk   Alemtuzumab
                                                          Atezolizumab
                                                          Avelumab
                                                          Asparaginase
                                                          Bevacizumab
                                                          Vleomycin
                                                          Blinatumomab
                                                          Bortezomib
                                                          Cetuximab
                                                          Cemiplimab
                                                          Cladribine
                                                          Cytarabine < 100 mg/m 2
                                                          Daratumumab
                                                          Daratumumab and hyluronidase-fihg
                                                          Decitabine
                                                          Denileukin diftitox
                                                          Dexrazosane
                                                          Duvalumab
                                                          Elotuzumab
                                                          Fludarabine
                                                          Ipilimumab
                                                          Lupatercept-aamt
                                                          Methotrexate ≤ 50 mg/m 2
                                                          Nelarabine



                                                        17
   12   13   14   15   16   17   18   19   20   21   22